Compounded Peptides ·
FDA removed tirzepatide from the drug shortage list in October 2024 after verifying that Eli Lilly had expanded manufacturing capacity sufficient to meet projected demand. Under federal law, the shortage designation is tied to the manufacturer's ability to supply the market, not to price or accessibility. Once supply was restored, the statutory basis for permitting wide-scale compounding of tirzepatide evaporated. Consumer advocacy groups and compounding industry associations argued that the agency's criteria were too narrow, but federal courts have generally upheld the FDA's authority to resolve shortage declarations as a factual matter. The 2026 regulatory landscape reflects this resolved designation.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.